Thus, the use of the selective COX-2 inhibitors was proved with multiple benefits; e.g., there can be increased efficiency of the antitumoral drugs (the tamoxifen benefits were more augmented in the patients with breast cancer with over-expression of COX-2 treated with COX-2 inhibitors, compared to those who did not receive) [160], there can be reduced the toxicity of the chemotherapeutics, and there can be increased the radiosensitivity of the tumor tissues [157]. The gene discussed is PTGS2; the disease is breast cancer.